8-K current report · filed Aug 13, 2026

Eton Pharmaceuticals, Inc. (ETON) 8-K Current Report: August 13, 2026

Item EX-99.1Item 2.02ETON overview

Short answer

Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Eton announced fiscal Q2 2026 results for the quarter ended June 30, 2026.

Eton Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Eton announced fiscal Q2 2026 results for the quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed financial results and management commentary
  • Adjusted EBITDA featured as management’s primary non-GAAP performance metric
  • Investors should reconcile Adjusted EBITDA with U.S. GAAP results before assessing profitability

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $37.6M, up 99% YoY, signaling rapid commercial scaling led by HEMANGEOL and portfolio-wide growth
  • GAAP diluted EPS $0.35, Adjusted EBITDA $16.2M, with margin expanding to 43% from 16%
  • 2026 guidance raised to revenue above $145M and Adjusted EBITDA margin at least 35%, versus prior thresholds of $120M and 30%
  • Growth investments add near-term cost risk: $3M ASN-001 licensing expense and potential $4M ALKINDI SPRINKLE milestone
  • ASN-001 targets potential H2 2027 NDA submission, while KHINDIVI label expansion could support approval in H1 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Eton Pharmaceuticals, Inc. 8-K filings

Get the next ETON 8-K as it lands

Follow ETON for push alerts, or ask the research agent what this filing means.